In a recent article, Benzinga featured the First Trust U.S. Equity Opportunities ETF (FPX), which tracks the IPOX® 100 U.S. Index, for being the first to add Medline Industries after its massive IPO. The piece highlights the fund's systematic, rules-based methodology, noting a 40% gain this year and a five-star Morningstar rating. This underscores how IPOX® indices provide investors with diversified, liquid access to top-performing new public companies like Medline.

Bill Ackman proposes a unique SpaceX merger, while Medtronic’s MiniMed and fleet AI firm Motive Technologies file for U.S. debuts. SoftBank delays its PayPay IPO to prioritize OpenAI funding, while China’s LandSpace and pet care group Ringpai advance listing plans. In Europe, Visma expands its syndicate for a blockbuster London deal, and Aegea files to break Brazil’s four-year IPO drought, as Seven & i accelerates its U.S. turnaround.

OpenAI and SpaceX headline the 2026 pipeline with potential $1 trillion+ valuations, fueling Nasdaq’s optimistic outlook. Andersen Group surged 31% in its debut, with IPOX® VP Kat Liu crediting strong brand recognition. In Europe, Elliott preps a London listing for Waterstones and Barnes & Noble. Meanwhile, a wave of Chinese AI and chip firms targets Hong Kong, while Saudi markets cool following EFSIM’s cancellation and CloudKitchens’ delay.

In a recent article by Reuters, tax advisory firm Andersen Group saw its shares surge 31% during its NYSE debut. Kat Liu, Vice President at IPOX, noted that investors are responding to the firm's unique brand legacy and earnings stability. With a $2.3 billion valuation, Andersen plans to use its new public currency for aggressive global acquisitions, signaling a revitalized momentum in the U.S. IPO market following recent interest rate cuts.

SpaceX dominates headlines with plans for a record-breaking IPO targeting a $1.5 trillion valuation. IPOX® CEO Josef Schuster weighs in on the blockbuster pipeline, while IPOX® Associate Lukas Muehlbauer analyzes Wealthfront’s debut and EquipmentShare’s filing. Tax firm Andersen targets a $1.75 billion deal, Michael Burry eyes a Fannie Mae re-listing, and Magnum completes its spin-off, while Hong Kong sees crypto and robotics activity.

IPOX® Research Analyst Lukas Muehlbauer was featured in Reuters discussing Wealthfront’s $2.63 billion Nasdaq debut. While the fintech raised $484.6 million, its flat opening highlighted ongoing market caution. Muehlbauer noted that "investors are still selective," distinguishing between high-profile wins and mixed broader performance. His commentary underscores the critical nuance required when analyzing shifting sentiment within the recovering fintech IPO landscape.

In a recent Reuters article, IPOX® CEO Josef Schuster analyzes the successful $462.5 million IPO of Lumexa Imaging amidst the year-end market rush. Schuster highlights that while investor appetite exists for the "right deal," there is notable caution regarding sectors with poor post-IPO returns, such as Silicon Valley-backed crypto and AI ventures. Read more about his insights on the current selective IPO landscape.

Construction tech firm EquipmentShare revealed significant revenue growth in its recent US IPO paperwork. IPOX® Research Analyst Lukas Muehlbauer provided key insights on the filing, noting the company’s sensitivity to interest rates due to capital deployment for its rental fleet. Muehlbauer also discussed the broader market trend, suggesting companies are rushing filings to avoid potential volatility and uncertainty surrounding Federal Reserve leadership changes in 2026.

In a recent Reuters article, IPOX® CEO Josef Schuster analyzes Medline’s targeted $55 billion listing, poised to be 2025’s largest IPO. Dr. Schuster highlights the deal as a critical test for market breadth beyond tech, describing the company as an "amazing American growth story." His commentary underscores the vital role of public markets in funding expansion as Medline seeks to raise over $5 billion in this blockbuster offering.

IPOX® Analyst Lukas Muehlbauer comments on Andersen Group's $1.75 billion IPO in a recent Reuters article. Muehlbauer describes the listing as a "resurrection story" for the brand formerly linked to Arthur Andersen. He notes that the decision to list now suggests management is prioritizing immediate capital access over 2026 volatility, while strategically aligning the deal with strong financial results from tax-extension seasonality.

A recent Bloomberg article examines the contraction of Canada’s public markets, where delistings are outpacing IPOs. IPOX® CEO Josef Schuster weighs in on the lack of domestic momentum, noting that Canadian firms are growing but often listing elsewhere. He emphasizes the need for a "strong first deal" to act as a catalyst and reignite the Canadian IPO market for the coming year.

AI takes the lead as Anthropic preps for a potential 2026 IPO and Baidu’s Kunlunxin eyes a Hong Kong listing. IPOX® Associate Lukas Muehlbauer comments on Wealthfront’s $2.05 billion target amid mixed sentiment. Elsewhere, Unilever’s ice cream unit advances spin-off plans, Barrick Gold explores a North American IPO, and Morgan Stanley predicts a dealmaking surge, even as travel unicorn Klook delays its U.S. debut.

In Kiplinger, David Milstead examines the surging U.S. IPO market, cautioning against risks from heavy AI and cryptocurrency concentration. He suggests navigating this volatility through diversified ETFs rather than individual stocks. Milstead highlights the First Trust US Equity Opportunities ETF (FPX), which tracks the IPOX® 100 U.S. Index. Up 39.3% in 2025, FPX captures major recent listings, offering investors broad exposure with reduced volatility compared to potentially riskier alternatives in this heated market.

Wealthfront targets a $2.05 billion valuation in its upcoming U.S. IPO. In recent Reuters coverage, IPOX® Associate Lukas Muehlbauer discusses the firm's strategic positioning at the "intersection of artificial intelligence and fintech." Muehlbauer highlights that while investor demand for new listings remains high, market sentiment is still susceptible to volatility. Read the full post for insights on Wealthfront’s plans and the current IPO market landscape.

Bill Ackman targets a massive $5 billion IPO for a new closed-end fund, while sports tech firm Enhanced agrees to a $1.2 billion SPAC merger. IPOX® CEO Josef Schuster notes the SPAC model’s enduring relevance following the deal. Elsewhere, the UK introduces stamp duty relief to revitalize London listings, and Hong Kong sees a flurry of activity with Syngenta’s potential pivot and new filings from Suzhou Novosense and Muyuan Foods.